Navigation Links
Progen Concedes Shareholder Requisitioned Meeting
Date:2/18/2009

ssible.

As a result of the current Progen board being unwilling to fully cooperate with the shareholder resolutions, the notice of meeting issued by Progen does not include any statement from shareholders. Instead, appropriate documentation addressing matters being put to shareholders at both meetings will be distributed shortly to Progen shareholders. It is important that all shareholders vote and fully understand all the choices being presented at each meeting.

Proposed Progen and Avexa merger

The material submitted by the Progen board on February 5, 2009 (Progen-Avexa Merger Notice of Meeting) details the high risk, high funding strategy that is being proposed under the merger with Avexa. This strategy is in stark contrast to the strategic recommendations arising from the company-commissioned Beerworth report and presented to Progen shareholders on November 13, 2008?

  • Adopt a policy of licensing an appropriate partner before commencing any future Phase III trial

-- Progen shareholders were advised of partnering interest in PI88

over a number of years, yet the company elected to take the

compound into Phase III trials and no partnering deal

eventuated. The Avexa merger proposes to focus investment in

the Phase III trials of Apricitabine (ATC).

-- ATC has also not been partnered and the total estimated cost of

completion of Phase III trials is $155 million. In the absence

of either substantial new capital or partnering and assuming

trial success, a further $95 million is likely to be needed to

achieve product registration.

  • Change emphasis from pursuing the registration and commercialisation of a single compound to a business model that inv
    '/>"/>

SOURCE Cytopia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytopia and Other Progen Shareholders Maintain Call for Meeting
2. Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders
3. Progentix Orthobiology and NuVasive Sign Investment Agreement
4. Red Herring Awards ProGenTech Limited for the 2008 Red Herring Asia 100
5. Progenitor Cell Therapy Secures Industry Accreditation
6. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
7. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
8. Progen Restructures Manufacturing and Drug Discovery Divisions
9. Progen Expands Board of Directors
10. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Omeros Corporation (NASDAQ: OMER ), ... and commercializing products targeting inflammation, coagulopathies and disorders ... Gregory A. Demopulos, M.D., chairman and chief executive ... and Renshaw 13th Annual Healthcare Conference taking place ...
... , Gains US Patent Protection for Proprietary AAV Intellectual ... leader in the field of human gene therapy, today ... agreement with the US National Institutes of Health (NIH) ... therapy vectors for liver and brain indications. This agreement ...
... This September, during Prostate Cancer Awareness Month , ... method that may change the face of prostate ... and one Boston hospital, analyzed by the National Cancer Institute, ... Dr. David Samadi, Vice Chairman, Department of Urology, and ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 2Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 3More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... New research from The University of Western Ontario leads ... the Arctic Circle during the Pleistocene Epoch (approx. 150,000 ... three years later than modern day African elephants due ... nursing pattern could have contributed to the prehistoric elephant,s ...
... 21, 2010 Reportlinker.com announces that a new market ... Indian Biometric Market http://www.reportlinker.com/p0351944/Indian-Biometric-Market.html ... fastest emerging technology in the Indian Securities & Identification ... many conventional methods of Identity & Security checks like, ...
... Miscanthus x giganteus is the forerunner in the ... researchers believe "putting all their eggs in one basket" could ... recently reported the first natural occurrence in several decades of ... M. x giganteus is the only variety available, ...
Cached Biology News:Being good moms couldn't save the woolly mammoth 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 3
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: